GSK's Virtual-Proof-of-Concept Unit in Tune with Lilly's Chorus
Many readers will have heard of Eli Lilly's Chorus initiative, designed to drive compounds through to proof-of-concept as cheaply and quickly as possible. A less well-publicized but similar discovery-on-a-budget initiative is GlaxoSmithKline's VPoC--virtual-proof-of-concept--unit.
You may also be interested in...
The pharmaceutical industry has a hard time saying goodbye to strategic assets. In fact, it’s much more adept at welcoming new ones: diversification – either geographic or into areas beyond pure-play pharmaceuticals – has become commonplace. But pharma needs to overcome its entrenched resistance to asset externalization, which should become a critical third leg in its attempts to build long-term shareholder value. Strategic, almost biotech-like externalization strategies should move from a peripheral to a core part of pharma’s activities. Why haven’t they already been embraced?
Facing a steep patent cliff and a dearth of late-stage drugs, Lilly is slashing expenses, reorganizing R&D, and hoping to attract investors to share the risks and rewards of pipeline development. Will these moves be enough?
Not satisfied with its R&D experiments to date, GSK has taken its most radical step yet toward re-creating biotech within its walls: even smaller units complete with investment boards occupied by external VCs and CEOs and milestone-based funding and external VCs.